So far 2026 has been a year of transition for healthcare and life sciences. Over the first half of this year, we’ve analyzed the individual stories moving the needle across the life sciences ecosystem as part of our Sector Spotlight series. The eight spotlights that follow in this recap capture a cross-section of this momentum: featuring the high-stakes battles for new drug markets (like oral GLP-1s and targeted radioligand therapies), a resurgent biotech IPO market, and the operational turnarounds keeping the back-end engine of medicine moving forward.
Follow the sector’s key debates during 2H26 and beyond, with our latest Sector Spotlights directly in AlphaSense. These eight debates include:
- CYTK vs. BMY in oHCM
- GSK’s Ozureprubart for Allergic Conditions
- Aktis Oncology vs. Novartis
- SpyGlass Pharma IPO
- Oral GLP1 Market
- Doximity: Reacceleration Prospects
- Avantor: Turnaround Progress
- uniQure: AMT130 for Huntingtonʼs Disease
